The estimated Net Worth of Randall Ph.D. Mrsny is at least $624 Tausend dollars as of 2 December 2022. Dr Mrsny owns over 418 units of Applied Molecular Transport stock worth over $5,495 and over the last 4 years he sold AMTI stock worth over $3,153. In addition, he makes $615,609 as Co-Founder und Chief Scientific Officer & Director at Applied Molecular Transport.
Dr has made over 4 trades of the Applied Molecular Transport stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 418 units of AMTI stock worth $439 on 2 December 2022.
The largest trade he's ever made was buying 3,500 units of Applied Molecular Transport stock on 9 December 2021 worth over $52,465. On average, Dr trades about 719 units every 51 days since 2021. As of 2 December 2022 he still owns at least 21,136 units of Applied Molecular Transport stock.
You can see the complete history of Dr Mrsny stock trades at the bottom of the page.
Dr. Randall Mrsny Ph.D. is the Co-Founder, Chief Scientific Officer & Director at Applied Molecular Transport.
As the Co-Founder und Chief Scientific Officer & Director of Applied Molecular Transport, the total compensation of Dr D at Applied Molecular Transport is $615,609. There are 1 executives at Applied Molecular Transport getting paid more, with Dr. Tahir Mahmood Ph.D. having the highest compensation of $621,009.
Dr D is 66, he's been the Co-Founder und Chief Scientific Officer & Director of Applied Molecular Transport since . There are no older and 8 younger executives at Applied Molecular Transport.
Randall's mailing address filed with the SEC is C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Applied Molecular Transport have traded over $9,673,149 worth of Applied Molecular Transport stock and bought 3,091,278 units worth $40,384,206 . The most active insiders traders include Capital Group, Llcepq Llc A..., Helen Susan Kim und Tahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of $26,155. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth $45,811.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Applied Molecular Transport executives and other stock owners filed with the SEC include: